Literature DB >> 3567010

Population study of triazolam pharmacokinetics.

H Friedman, D J Greenblatt, E S Burstein, J S Harmatz, R I Shader.   

Abstract

The kinetics of a single 0.5 mg oral dose of the triazolobenzodiazepine hypnotic triazolam, were studied in 54 healthy young men aged 20-44 years, with a mean body weight of 77 kg. Triazolam kinetics were determined from multiple plasma concentrations measured during 14 h post-dose. The overall mean +/- s.e. mean (with range) kinetic variables were: peak plasma concentration, 4.4 +/- 0.3 (1.7-9.4) ng ml-1; time of peak, 1.3 +/- 0.1 (0.5-4.0) h after dose; elimination half-life, 2.6 +/- 0.1 (1.1-4.4) h; total AUC: 19.1 +/- 1.1 (4.4-47.7) ng ml-1 h; oral clearance, 526 +/- 38 (175-1892) ml min-1. All kinetic variables were consistent with Poisson distributions, based on the Kolmogorov-Smirnov Goodness of Fit test. None of the variables fit normal distributions. Four of five were consistent with a log normal distribution. Peak plasma level was highly correlated with clearance (r = -0.85, P less than 0.0001), and AUC (r = 0.85, P less than 0.0001) but not with body weight (r = 0.21, NS). Clearance and body weight were not correlated (r = -0.01). Triazolam clearance may vary widely even within a homogeneous group of healthy young men.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3567010      PMCID: PMC1401197          DOI: 10.1111/j.1365-2125.1986.tb02951.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

Review 1.  Clinical pharmacokinetics (second of two parts).

Authors:  D J Greenblatt; J Koch-Weser
Journal:  N Engl J Med       Date:  1975-11-06       Impact factor: 91.245

2.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

3.  Enhanced bioavailability of triazolam following sublingual versus oral administration.

Authors:  J M Scavone; D J Greenblatt; H Friedman; R I Shader
Journal:  J Clin Pharmacol       Date:  1986-03       Impact factor: 3.126

4.  Effect of subject age and gender on the pharmacokinetics of oral triazolam and temazepam.

Authors:  R B Smith; M Divoll; W R Gillespie; D J Greenblatt
Journal:  J Clin Psychopharmacol       Date:  1983-06       Impact factor: 3.153

5.  Electron-capture gas chromatographic analysis of the triazolobenzodiazepines alprazolam and triazolam.

Authors:  D J Greenblatt; M Divoll; L J Moschitto; R I Shader
Journal:  J Chromatogr       Date:  1981-09-11

Review 6.  Estimating population kinetics.

Authors:  S L Beal; L B Sheiner
Journal:  Crit Rev Biomed Eng       Date:  1982

7.  The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam.

Authors:  D R Abernethy; D J Greenblatt; M Divoll; R B Smith; R I Shader
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

8.  Pharmacology and hypnotic efficacy of triazolam.

Authors:  T Roth; T A Roehrs; F J Zorick
Journal:  Pharmacotherapy       Date:  1983 May-Jun       Impact factor: 4.705

9.  Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity.

Authors:  D J Greenblatt; M Divoll; D R Abernethy; L J Moschitto; R B Smith; R I Shader
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

10.  Triazolam disposition.

Authors:  F S Eberts; Y Philopoulos; L M Reineke; R W Vliek
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875

  10 in total
  17 in total

1.  Forensic analysis of triazolam in human tissues using capillary gas chromatography.

Authors:  K Kudo; T Nagata; T Imamura; S Kage; Y Hida
Journal:  Int J Legal Med       Date:  1991-03       Impact factor: 2.686

2.  Alcohol, drugs and driving: implications for evaluating driver impairment.

Authors:  Timothy Brown; Gary Milavetz; Daryl J Murry
Journal:  Ann Adv Automot Med       Date:  2013

3.  Three cases of fatal triazolam poisoning.

Authors:  J P Sunter; T S Bal; W K Cowan
Journal:  BMJ       Date:  1988-09-17

4.  Zolpidem and triazolam do not affect the nocturnal sleep-induced memory improvement.

Authors:  Jaime Meléndez; Irina Galli; Katica Boric; Alonso Ortega; Leonardo Zuñiga; Carlos F Henríquez-Roldán; Ana M Cárdenas
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

Review 5.  Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology.

Authors:  L L von Moltke; D J Greenblatt; J Schmider; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

6.  Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. II. Triazolam.

Authors:  S K Gupta; E H Ellinwood; A M Nikaido; D G Heatherly
Journal:  Pharm Res       Date:  1990-06       Impact factor: 4.200

Review 7.  Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment.

Authors:  P Gaudreault; J Guay; R L Thivierge; I Verdy
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

8.  Reversal of triazolam- and zolpidem-induced memory impairment by flumazenil.

Authors:  N J Wesensten; T J Balkin; H Q Davis; G L Belenky
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

9.  A survey of the likelihood approach to bioequivalence trials.

Authors:  Leena Choi; Brian Caffo; Charles Rohde
Journal:  Stat Med       Date:  2008-10-30       Impact factor: 2.373

10.  Difference in action between oral triazolam and zopiclone.

Authors:  R Aantaa; M Salonen; T Nyrke
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.